These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31404304)

  • 61. Cytogenetic, fluorescence in situ hybridization, and molecular characterization of chronic myeloid leukemia in chronic phase with four BCR/ABL1 fusion signals: a case report.
    Vargas MT; Portero MA; Rodríguez A; Reyes J; Fernández-Novoa C
    Cancer Genet Cytogenet; 2009 Nov; 195(1):71-4. PubMed ID: 19837272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia.
    Löf L; Arngården L; Olsson-Strömberg U; Siart B; Jansson M; Dahlin JS; Thörn I; Christiansson L; Hermansson M; Larsson A; Ahlstrand E; Wålinder G; Söderberg O; Rosenquist R; Landegren U; Kamali-Moghaddam M
    Sci Rep; 2017 Apr; 7(1):623. PubMed ID: 28377570
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia.
    Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Kearney HM; Greipp PT; Hoppman NL; Baughn LB; Ketterling RP
    Hum Pathol; 2019 Jul; 89():109-114. PubMed ID: 30267776
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Raj TVA; Priya G; Nair JKKM; Sreedharan H
    Gene; 2019 Feb; 686():85-91. PubMed ID: 30399426
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph negative chronic myeloid leukemia.
    Michalová K; Zemanová Z; Bkezinová J; Moravcová J; Oltová A; Sobotka J; Kuglík P; Kozak T; Sindelarová L; Jankovská M; Obomilová A; Sieglová Z; Polák J; Nádvorníková S; Haskovec C
    Leuk Lymphoma; 2002 Aug; 43(8):1695-700. PubMed ID: 12400616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
    Vacarean-Trandafir IC; Ivanov IC; Dragos LM; Dascalescu AS; Titieanu AA; Cojocaru D
    Mol Biol Rep; 2019 Aug; 46(4):3747-3754. PubMed ID: 31025148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
    Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
    Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia.
    Dasgupta S; Ray UK; Mitra AG; Bhattacharyya DM; Mukhopadhyay A; Das P; Gangopadhyay S; Roy S; Mukhopadhyay S
    Blood Res; 2017 Jun; 52(2):112-118. PubMed ID: 28698847
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review.
    Manda-Mapalo MT; Khalili P; Quintana D; Rabinowitz I; Zhang QY
    Cancer Genet; 2016 Oct; 209(10):481-485. PubMed ID: 27810077
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Detection of bcr/abl fusion transcripts by semiquantitative multiplex RT-PCR combined with a colormetric assay in Ph positive leukemia.
    Ni H; Nitta M; Komatsu H; Kojima S; Suzuki S; Harada S; Tsuboi K; Banno S; Wakita A; Yazaki M; Ren L; Kato T; Ueda R
    Cancer Lett; 1998 Feb; 124(2):173-80. PubMed ID: 9500207
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
    Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
    Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
    Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
    Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
    Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias.
    Burmeister T; Gröger D; Kühn A; Hoelzer D; Thiel E; Reinhardt R
    DNA Repair (Amst); 2011 Nov; 10(11):1131-7. PubMed ID: 21944569
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.
    Cumbo C; Impera L; Minervini CF; Orsini P; Anelli L; Zagaria A; Coccaro N; Tota G; Minervini A; Casieri P; Brunetti C; Rossi AR; Parciante E; Specchia G; Albano F
    Oncotarget; 2018 Feb; 9(13):10978-10986. PubMed ID: 29541390
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients.
    Mir R; Ahmad I; Javid J; Zuberi M; Yadav P; Shazia R; Masroor M; Guru S; Ray PC; Gupta N; Saxena A
    Indian J Cancer; 2015; 52(3):314-8. PubMed ID: 26905124
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Extramedullary blast crisis as initial presentation in chronic myeloid leukemia with the e1a2 BCR-ABL1 transcript: A case report.
    Ai DI; Liu W; Lu G; Patel KP; Chen ZI
    Mol Clin Oncol; 2015 Nov; 3(6):1319-1322. PubMed ID: 26807241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.